Myositis

Myositis

Comparative, Double-Blind, Investigational Study Evaluating the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM)

• You Must:
  • Be diagnosed of definite or probable IIM
  • Demonstrate muscle weakness
  • Have active disease despite adequate prior treatment experience with corticosteroids, immunosuppressants, or biologic medications

• You Must Not:
  • Have Inclusion Body Myositis or myositis other than IIM
  • Have been treated with rituximab in the past year or any other biologic treatment or IVIG in the past 6 months

• This is a 52 week long investigational study – Visits occur at Screening, Baseline, and about every 4 weeks afterwards
• For more information, please contact (610) 868-1336 ext. 112